Related Experiment Video
Updated: May 26, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Echinocandins: are they all the same?
P K Mukherjee1, D Sheehan, L Puzniak
1Center for Medical Mycology and Mycology Reference Laboratory, Department of Dermatology, University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio 44106, USA.
Abstract:
The discovery of echinocandins, and their development and approval, was hailed as a significant addition to our antifungal armamentarium, previously predominated by polyenes and azoles. To date, three echinocandins (anidulafungin, caspofungin, and micafungin) have been approved by the U.S. Food and Drug Administration for the treatment of fungal infections. Since all three echinocandins target the fungal cell wall and share a similar structural chemical backbone, they are perceived to be identical. However, a scientific literature review shows distinct differences among the echinocandins in terms of in vitro activity, fungicidal activity, post-antifungal effect, paradoxical effect, and activity on biofilms. More investigation is warranted to determine if the observed differences among the echinocandins can translate to clinical advantages.
Related Concept Videos
Antifungal Agents
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Inhibitors of Bacterial Protein Synthesis
Chirality in Nature
Bioequivalence: Overview
Dose-Response Relationship: Potency and Efficacy

